Notice: This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends FSDC vs. CPRX, EWTX, ARWR, AMRX, MIRM, GMTX, CNTA, HCM, BHC, and PTGXShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Catalyst Pharmaceuticals (CPRX), Edgewise Therapeutics (EWTX), Arrowhead Pharmaceuticals (ARWR), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Centessa Pharmaceuticals (CNTA), HUTCHMED (HCM), Bausch Health Companies (BHC), and Protagonist Therapeutics (PTGX). These companies are all part of the "medical" sector. FS Development vs. Catalyst Pharmaceuticals Edgewise Therapeutics Arrowhead Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Gemini Therapeutics Centessa Pharmaceuticals HUTCHMED Bausch Health Companies Protagonist Therapeutics FS Development (NASDAQ:FSDC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Do insiders & institutionals believe in FSDC or CPRX? 89.8% of FS Development shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in FSDC or CPRX? Catalyst Pharmaceuticals received 500 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformFS DevelopmentN/AN/ACatalyst PharmaceuticalsOutperform Votes50074.96% Underperform Votes16725.04% Which has higher valuation & earnings, FSDC or CPRX? Catalyst Pharmaceuticals has higher revenue and earnings than FS Development. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFS DevelopmentN/AN/AN/AN/AN/ACatalyst Pharmaceuticals$398.20M6.48$71.41M$1.1818.33 Do analysts prefer FSDC or CPRX? Catalyst Pharmaceuticals has a consensus price target of $32.25, indicating a potential upside of 49.13%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is FSDC or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to FS Development's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat FS Development's return on equity.Company Net Margins Return on Equity Return on Assets FS DevelopmentN/A N/A N/A Catalyst Pharmaceuticals 31.01%40.79%34.87% Does the media prefer FSDC or CPRX? In the previous week, Catalyst Pharmaceuticals had 4 more articles in the media than FS Development. MarketBeat recorded 4 mentions for Catalyst Pharmaceuticals and 0 mentions for FS Development. Catalyst Pharmaceuticals' average media sentiment score of 0.65 beat FS Development's score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment FS Development Neutral Catalyst Pharmaceuticals Positive SummaryCatalyst Pharmaceuticals beats FS Development on 12 of the 13 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$682.50M$7.04B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.86%P/E RatioN/A6.1426.7919.19Price / SalesN/A267.56434.7870.88Price / CashN/A65.6738.0134.83Price / BookN/A6.707.644.62Net IncomeN/A$138.98M$3.19B$246.06M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$54.53+0.3%N/A-18.2%$682.50MN/A0.00N/ACPRXCatalyst Pharmaceuticals4.8604 of 5 stars$22.76-0.6%$32.25+41.7%+57.7%$2.71B$460.48M19.2980Upcoming EarningsEWTXEdgewise Therapeutics1.8167 of 5 stars$26.34-0.1%$41.29+56.7%+54.7%$2.49BN/A-17.5660Upcoming EarningsARWRArrowhead Pharmaceuticals4.0859 of 5 stars$19.92-1.6%$43.33+117.5%-31.8%$2.49B$3.55M-3.97400AMRXAmneal Pharmaceuticals3.7579 of 5 stars$7.95+1.3%$10.00+25.8%+36.6%$2.46B$2.68B-11.697,700MIRMMirum Pharmaceuticals2.6984 of 5 stars$50.46-1.2%$57.10+13.2%+85.6%$2.42B$186.37M-24.98140News CoverageGMTXGemini TherapeuticsN/A$54.82-2.6%N/A-18.2%$2.38BN/A-54.8230News CoverageCNTACentessa Pharmaceuticals3.2926 of 5 stars$17.79-6.5%$25.83+45.2%+59.9%$2.35B$6.85M-11.63200Insider TradeHigh Trading VolumeHCMHUTCHMED1.5946 of 5 stars$13.42+1.4%$19.00+41.6%+11.3%$2.34B$610.81M0.001,988News CoverageGap UpBHCBausch Health Companies3.86 of 5 stars$6.32-2.1%$7.42+17.4%-15.7%$2.33B$9.47B-13.1620,270Earnings ReportNews CoveragePTGXProtagonist Therapeutics3.6999 of 5 stars$37.99-2.3%$56.00+47.4%+44.7%$2.32B$323.80M14.28120Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap Up Related Companies and Tools Related Companies Catalyst Pharmaceuticals Competitors Edgewise Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Gemini Therapeutics Competitors Centessa Pharmaceuticals Competitors HUTCHMED Competitors Bausch Health Companies Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FSDC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
